A new federal clinical trial exploring the use of MDMA-assisted therapy for veterans struggling with severe mental health conditions is set to begin under the U.S. Department of Veterans Affairs, marking one of the government’s most significant steps yet into psychedelic-based medical research.
The announcement, made Tuesday by the Department of Veterans Affairs, outlines a new randomized clinical study designed to evaluate whether MDMA-assisted therapy can safely and effectively help veterans diagnosed with post-traumatic stress disorder, commonly known as PTSD, along with alcohol use disorder. The trial comes amid growing national interest in alternative mental health treatments as traditional therapies continue to show mixed results for some patients, particularly combat veterans and others suffering from long-term trauma.
The study, officially titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans,” is expected to enroll approximately 80 veterans. Participants will either receive MDMA-assisted therapy or identical psychotherapy sessions paired with an active placebo for comparison purposes.
Federal officials say the study is being conducted under tightly controlled medical conditions and will involve pharmaceutical-grade MDMA administered in structured therapeutic settings with trained professionals present throughout treatment sessions.
The clinical trial will be conducted through the VA Providence Healthcare System, with recruitment focused on veterans connected to the Providence, Rhode Island, VA campus and the VA Connecticut Healthcare System in West Haven, Connecticut.
The move follows a recent executive order signed by President Donald Trump aimed at accelerating research and treatment options for severe mental illness. The order encourages expanded clinical trial participation and seeks to speed up the development and review of emerging therapies, including psychedelic compounds that have increasingly drawn attention within psychiatric research communities.
VA Secretary Doug Collins described the trial as part of a broader effort to address growing mental health challenges facing veterans nationwide.
“We need an all-of-the-above strategy when it comes to improving mental health treatments,” Collins said in the department’s announcement. “This trial represents an important step in safely evaluating new approaches and innovations to treat Veterans with severe mental health conditions.”
PTSD remains one of the most persistent and difficult mental health conditions affecting military veterans. Symptoms can include severe anxiety, depression, emotional numbness, flashbacks, insomnia, substance abuse and suicidal thoughts. According to federal health data, veterans experience elevated rates of PTSD compared to the general population, particularly those exposed to combat or traumatic military experiences.
MDMA, sometimes referred to on the street as ecstasy or molly, is classified as a psychedelic and empathogenic substance capable of altering mood, perception and emotional processing. While the drug remains illegal for recreational use under federal law, researchers over the past decade have increasingly studied its potential therapeutic role when administered in medically supervised environments.
The Food and Drug Administration has already granted breakthrough therapy designation to several psychedelic-related treatments, including MDMA, psilocybin and LSD. That designation is intended to speed the review process for treatments showing early promise for serious or life-threatening conditions.
Despite the expanding research efforts, the Department of Veterans Affairs emphasized that psychedelic-assisted therapies remain experimental and are not currently approved for routine clinical use within the VA healthcare system.
Federal officials also stressed that veterans should not attempt to self-medicate using psychedelic substances outside approved medical research settings. The department warned that unsupervised use of such substances may carry serious health and psychological risks.
According to the VA, all psychedelic-related research conducted through the agency follows strict federal safety requirements and oversight protocols developed in coordination with the FDA. Participants in the new MDMA study will undergo structured psychotherapy and close medical monitoring throughout the process.
The department says it is currently involved in 19 active clinical trials involving psychedelic therapies and mental health treatment. Those projects are supported by more than $23 million in outside funding.
The growing federal interest in psychedelic-assisted therapy reflects a larger shift occurring throughout the medical and psychiatric fields as researchers search for alternatives to conventional antidepressants and trauma therapies. Several universities, hospitals and private research institutions across the United States are now conducting studies involving psychedelics for conditions ranging from severe depression and addiction to anxiety disorders and end-of-life psychological distress.
Whether MDMA-assisted therapy ultimately receives full FDA approval remains uncertain, but the launch of a federally coordinated VA trial signals that psychedelic research is increasingly moving from the fringes of medicine into mainstream clinical evaluation.
Veterans interested in participating in the trial are encouraged to contact the participating VA healthcare systems for screening and eligibility information. The study is also registered through ClinicalTrials.gov.